Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist1.

ZYVOX offers effective intervention for nosocomial pneumonia, community acquired pneumonia and complicated skin and soft tissue infections caused by susceptible Gram positive pathogens1

  • ZYVOX is active against Gram positive, aerobic and anaerobic pathogens, including staphylococci, enterococci and streptococci1
  • ZYVOX is not active against infections caused by Gram negative pathogens1
Full preview

Illustration adapted from ZYVOX Summary of Product Characteristics1

 

Susceptible Organisms Resistant Organisms

Gram-positive aerobes:

Enterococcus faecalis

Enterococcus faecium*

Staphylococcus aureus*

Coagulase negative staphylococci

Streptococcus agalactiae*

Streptococcus pneumoniae*

Streptococcus pyogenes*

Group C streptococci

Group G streptococci

Gram-positive anaerobes:

Clostridium perfringens

Peptostreptococcus anaerobius

Peptostreptococcus species

Haemophilus influenzae

Moraxella catarrhalis

Neisseria species

Enterobacteriaceae

Pseudomonas species

 *Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications. Whereas linezolid shows some in vitro activity against Legionella, Chlamydia pneumoniae and Mycoplasma pneumoniae, there are insufficient data to demonstrate clinical efficacy.

Table adapted from ZYVOX Summary of Product Characteristics1.


References

  1. ZYVOX® Summary of Product Characteristics